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Aim: Pharmacokinetics after oral microdosing of the anticipated CYP2D6 substrate yohimbine and its
metabolite 11-OH-yohimbine is potentially useful for drug–drug interaction trials and profiling of CYP2D6
enzyme activity. Materials & methods: We developed an ultrasensitive ultra performance liquid chro-
matography coupled to tandem mass spectrometry assay for quantification of yohimbine and its main
metabolite 11-OH-yohimbine in plasma with a linear calibration range of 5–2500 pg/ml and validated
it according to US FDA’s and EMA’s guidelines. Sample preparation was performed using fast liquid–
liquid extraction. The assay was applied for the determination of concentrations of yohimbine and 11-
OH-yohimbine in plasma after oral administration of 50 μg yohimbine to two subjects. Conclusion: Ultra-
sensitive quantification of yohimbine and itsmetabolite enables the determination of their concentrations
in plasma after microdosing which would be applicable to use in CYP2D6 phenotyping.
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The pharmacologically sparsely describedα2-receptor antagonist yohimbine is licensed in Germany for the treatment
of erectile dysfunction with recommended daily doses of 10–30 mg. Its mechanism of action is not yet fully
understood [1], yet impacts on the penile venous blood vessels [2] or in the central nervous system [3] are considered
to play a part. While yohimbine is losing importance for erectile dysfunction therapy, it is found in many dietary
supplements for enhancing libido, for weight loss and as aid for bodybuilding [4].
Yohimbine is metabolized primary into the active metabolite 11-OH-yohimbine and to a smaller extent into
10-OH-yohimbine [5–7]. In vitro data indicate that CYP2D6 is likely to be involved in the metabolism of yohimbine
to 11-OH-yohimbine [8]. CYP2D6 undergoes a genetic polymorphism resulting in highly variable activity with
approximately 10% of the European population being CYP2D6 poor metabolizers [9]. Monitoring enzyme activity
during early phase clinical trials and also in drug–drug interaction trials is gaining importance since the introduction
of microdosing. A microdose is characterized as being 1/100th of the pharmacologically active dose or 100 μg,
whichever is the lower amount and causes no demonstrable pharmacodynamic effect. Such a dosing regimen
improves the safety of participants in drug–drug interaction trials and is advantageous because the microdosed
probe drugs do not act as perpetrators and thus can be used in substrate cocktails.
Only a few analytical assays to quantify yohimbine have been described in the literature and these used liquid–
liquid extraction with alkaline buffer and organic solvents for sample preparation with large plasma volumes of
0.5–2 ml. Normal phase or reversed-phase C8 columns for liquid chromatography were coupled to electrochemical
or fluorimetric detection. A recent method used protein precipitation for extraction and quantified yohimbine via
LC–MS/MS showing an lower limit of quantification (LLOQ) of 0.1 ng/ml for yohimbine. 11-OH-yohimbine
has been quantified only by fluorimetric detection with an LLOQ of 1 ng/ml [6,10].
To prove the suitability of microdosed oral yohimbine administration for potential drug–drug interaction
trials, we developed an ultra performance liquid chromatography coupled to tandem mass spectrometry (UPLC–
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MS/MS) assay with positive electrospray ionization and multiple reaction monitoring (MRM) for simultaneous
quantification of yohimbine and 11-OH-yohimbine in the picogram range utilizing liquid–liquid extraction for
sample preparation and validated the assay according to the pertinent guidelines of US FDA and EMA [11,12]. The
method was successfully applied for the quantification of concentrations of yohimbine and 11-OH-yohimbine in
plasma from two healthy subjects who received a single oral dose of 50 μg yohimbine.
Materials & methods
Drugs, chemicals, solvents & materials
Yohimbine hydrochloride was kindly provided by Herband Pharmachemicals (Gengenbach, Germany). Pierre Fabre
laboratoires (Toulouse, France) kindly donated 11-OH-yohimbine (5.1 mg, 98% purity) and internal standard
(IS; [13C2H3]-yohimbine) was purchased from Alsachim (Illkirch, France). Yohimbine tablets for oral microdoses
(Yohimbinum hydrochloricum D4 R©) were purchased from Deutsche Homo¨opathie Union (Karlsruhe, Germany).
Boric acid and ammonium acetate were obtained from Sigma-Aldrich (Darmstadt, Germany). Acetonitrile (ACN),
isopropanol, acetic acid, formic acid (FA), sodium hydroxide, methyl tert-butyl ether (TBME) and methanol were
purchased from Biosolve BV (Valkenswaar, The Netherlands) in the highest available purity (ULC/MS grade). For
calibration standards, quality controls (QCs) and validation-purpose drug-free plasma from healthy subjects were
obtained at the local blood bank.
Clinical study & preparation of plasma samples
The competent authority (Bundesinstitut fu¨r Arzneimittel und Medizinprodukte, Germany) and the Ethics Com-
mittee of the Medical Faculty of Heidelberg (Germany) approved the clinical trial protocol (EudraCT 2017-
001801-34). The trial was conducted at the Clinical Research Unit (KliPS, certified according to ISO 9001:2015)
of the Department of Clinical Pharmacology and Pharmacoepidemiology in accordance with German legal require-
ments, good clinical practice guidelines and Declaration of Helsinki. Healthy subjects supplied written consent
before participation. After oral administration of 50 μg yohimbine, blood samples were taken into heparinized
tubes (7.5 ml, S-Monovette R©, Sarstedt AG, Nu¨mbrecht, Germany) before and at 0.25, 0.5, 0.75, 1, 1.25, 1.5,
1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, as well as 24 h after administration. After centrifugation (3600 × g, 10 min, 4◦C)
plasma samples were stored in aliquots at -25◦C until analysis.
Standard preparation
For the IS solution [13C2H3]-yohimbine was dissolved in ACN/water (1:1, v/v, 1 mg/ml) and diluted to a
concentration of 100 ng/ml. For standard stock solutions, yohimbine (3.11 mg) and 11-OH-yohimbine (2.05 mg)
were dissolved in ACN/water (1:1, v/v), subsequently combined and further diluted to yield calibration working
solutions.
Stock solutions for QC samples were weighed independently and prepared as described for calibration solutions.
Calibration & QC samples
Samples for calibration and QCs were prepared by spiking blank plasma (100 μl) with 25 μl of the corresponding
calibration or QC working solutions to provide calibration concentrations of 5, 10, 50, 100, 250, 500, 1000 and
2500 pg/ml and QC concentrations of 8.50, 199 and 1986 pg/ml (yohimbine) and 9.74, 195 and 1948 pg/ml
(11-OH-yohimbine).
Liquid–liquid extraction for plasma sample preparation
The respective working solutions (25 μl) were spiked to blank plasma (100 μl) in plastic tubes (10 ml) for
preparation of calibration and QC samples. For volume compensation study samples (100 μl) were spiked with
ACN/water (25 μl, 1:1, v/v). Each sample was additionally spiked with IS solution (25 μl). After addition of
borate buffer pH 9 (100 μl) samples were vortexed and TBME (2 ml) was added. After shaking (10 min) and
centrifugation (10 min, 3600 × g), the organic phase (1.5 ml) was transferred into glass tubes and evaporated to
dryness under a stream of nitrogen at 40◦C. UPLC eluent (100 μl, ACN/water; 5:95 v/v with 0.1 % FA) was used
for reconstitution of the residue. After shaking on a vortex-mixer and sonication, the solution was transferred to a
96-well collection plate (800 μl, Waters, MA, USA).
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Instrumental analysis parameters
The UPLC–MS/MS system (Waters) consisted of an Acquity UPLC R© system including a Waters Sample Manager,
binary solvent manager, cooled sample trays, integrated column heater and degasser coupled to a triple-stage
quadrupole mass spectrometer (Xevo TQ-S, Waters) equipped with Z-spray ionization.
Chromatographic separation was achieved at 40◦C on a Waters Acquity BEH C18 column (1.7 μm,
2.1 × 50 mm) including an integrated filter disc. The injection volume was 20 μl and the eluent consisted
of water including 5% ACN and 0.1 % FA (A) and ACN including 0.1 % FA (B) at a flow rate of 0.5 ml/min. The
gradient started at 95% A/5% B and held for 0.1 min and then changed within 2 min to 5% A/95% B, kept at
these conditions until 2.5 min and changed at 3 min back to 95% A/5% B. Ionization parameters were as follows:
spray voltage 500 V, cone voltage 25 V, cone gas flow (N2) 150 l/h, desolvation temperature 600◦C, desolvation
gas flow (N2) 1000 l/h, source temperature 150◦C. Tuning of the Xevo TQ-S to yohimbine, 11-OH-yohimbine
and labeled IS was performed automatically using the integrated software package (MassLynx V4.1) and IntelliStart
standard procedures. For collision induced decomposition (CID), argon was used as collision gas at a flow rate
of 0.15 ml/min. MS/MS transitions for MRM in positive ionization mode were m/z 355.2→144.2 at 30 V for
yohimbine (quantifier), m/z 355.2→212.2 at 30 V for yohimbine (qualifier), m/z 359.2→144.2 at 30 V for
[13C2H3]-yohimbine and m/z 371.2→160.2 at 24 V for 11-OH-yohimbine (quantifier) and m/z 371.2→212.2
at 24 V for 11-OH-yohimbine (qualifier). Dwell time for each transition was 0.063 s resulting in a total cycle time
of 0.315 s.
Validation
Validation of the assay was conducted in accordance with the guidelines recommended by the FDA and EMA.
Three validation batches were analyzed, each including eight calibration samples and 24 QC samples (LLOQ; QC
A; QC B; QC C). Accuracy (%) was calculated as ratio of the average concentration values measured in respective
batches divided by the nominal concentrations. Precision (%) was determined as ratio of standard deviation and the
mean sample concentration. For determination of selectivity blank plasma of six different individuals was analyzed
as described without spiking analyte or IS. Recovery was investigated by comparison of peak area of QC samples
divided by the corresponding peak areas of blank plasma spiked with the respective QC solutions after extraction
(100% analyte in the same matrix). Stability was demonstrated by determination of QCs after three freeze—thaw
cycles, lasting at least 24 h. Stability of extracts during analyses was proven by repeated measurement of QCs after
staying in the autosampler at 15◦C over night.
Statistical & calculation methods
Calibration plasma samples and their respective quantifier MRM transitions were used to generate calibration
curves for yohimbine and 11-OH-yohimbine. TargetLynx V4.1 (Waters) software was used to calculate peak area
ratios of analytes and IS and weighted linear regression (1/x) was performed. For pharmacokinetic data analysis
Kinetica 5.0 (Thermo Fisher Scientific, MA, USA) was used and graphs created by Prism 7.02 (Graphpad, CA,
USA).
Results & discussion
Sample preparation
Best results for sample preparation were achieved by liquid–liquid extraction using borate buffer pH 9 and TBME.
Analyte plasma recovery was determined from QCs A–C in triplicates and ranged between 80.7 and 108% for
yohimbine, 86.7 and 98.2% for 11-OH-yohimbine and 92.4 and 110% for [13C2H3]-yohimbine. These consistent
recoveries of yohimbine and its metabolite 11-OH-yohimbine confirm the suitability of the IS to account for the
extraction characteristics of both analytes which resulted in precise quantification despite no separate isotopically
labeled standard for 11-OH-yohimbine.
Chromatography & mass spectrometry
A Waters BEH C18 UPLC column (1.7 μm) and a fast gradient from 5 to 95% organic solvent achieved baseline
separated peaks and a short run time of 3 min (Figure 1). The fast and steep gradient was necessary to achieve
sharp peaks for 11-OH-yohimbine because slower gradients led to a substantial increase in peak width impeding
sensitive quantification.
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Figure 1. Ultra performance liquid chromatography coupled to tandem mass spectrometry chromatograms of
processed plasma samples with mass transitions of yohimbine (top trace), [13C2H3]-yohimbine (middle trace),
11-OH-yohimbine (bottom trace) shown separately. (A) Blank plasma sample. (B) Plasma sample spiked at lower limit
of quantification concentration. (C) Plasma sample spiked at quality control B concentration. (D) Plasma sample of
subject 1, 2 h after oral administration of 50 μg yohimbine (calculated yohimbine concentration: 79.9 pg/ml and
calculated 11-OH-concentration: 218 pg/ml).
Positive electrospray ionization generated intense [M + H]+ signals when using acidic eluents for both analytes
and the IS. The [M + H]+ signal for yohimbine at m/z 355.2 showed highest intensity and hence was used for
quantification. For the IS and 11-OH-yohimbine, a mass shift of m/z 4 for the IS and m/z 16 for the corresponding
[M + H]+ ions used for quantification were observed at m/z 359.2 and m/z 371.2, respectively.
CID of yohimbine generated two abundant product ions at m/z 144.2 and m/z 212.2 with the m/z 144.2
showing considerable higher intensity (Figure 2). The same pattern was observed for the IS with a mass shift of
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Figure 2. Positive product ion spectrum of the [M + H]+ yohimbine signal at m/z 355. In the chemical structure, the
star depicts the position of the methyl group labeled with 13C and 2H3 in the internal standard and the position of
the hydroxyl group in the metabolite 11-OH-yohimbine is implied by the dashed line.
4 Da at the less intense fragment yielding product ions at m/z 144.2 and m/z 216.2. 11-OH-yohimbine also
showed two main product ions at m/z 160.2 and m/z 212.2 in CID. The mass shift of 16 Da for the more intense
fragment corresponds to the additional oxygen of the hydroxyl group in comparison to yohimbine. Due to the
almost exclusive abundance of the two product ions, only one major decomposition is anticipated for yohimbine
as well as 11-OH-yohimbine which is depicted in Figure 2 producing the two observed product ions, most likely
as [M + H]+ signals.
The more intense fragment was hence chosen for quantification while the less intense product ion served as
a qualifier transition increasing specificity of the detection. Identity of the product ions was investigated by high
resolution mass spectrometry using a Xevo-G2-XS quadrupole time of flight mass spectrometer (Waters) and in
accordance with the suspected structures: product ions of yohimbine, 11-OH-yohimbine and [13C2H3]-yohimbine
showed m/z values of 144.0826 and 212.1301, 160.0775 and 212.1300, as well as 144.0836 and 216.1512; in
accordance with the theoreticalm/z values of 144.0813 and 212.1287, 160.0757 and 212.1287, as well as 144.0808
and 216.1509, respectively.
Validation
Validation results fully complied with the requirements of FDA’s and EMA’s guidelines for bioanalytical method
validation. Absence of interference in blank plasma of six different individuals proved selectivity of the assay
(Figure 1). Within-batch accuracies for analytes at the LLOQ level ranged from 102 to 117% with maximum
deviation of precision of 10.8%. Batch-to-batch accuracies ranged from 99.8 to 111% with a maximum precision
deviation of 8.40%. For QC A–C within-batch accuracies ranged from 86.0 to 106% with a maximum precision
deviation of 4.60% and batch-to-batch accuracies from 87.2 to 104% with a maximum deviation of precision of
6.30% for both analytes. Complete results of the assay validation are shown in Table 1.
Correlation coefficients for linear regression were >0.997 for yohimbine and 11-OH-yohimbine (weighting 1/x).
Stability in plasma samples was demonstrated for QC A–C after three freeze-and-thaw cycles with corresponding
accuracies ranging from 94.8 to 114.9%, and plasma extracts were stable after remaining in the autosampler at
15◦C for 24 h.
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Table 1. Validation results for quality controls.
Within-batch LLOQ QC A QC B QC C
Yohimbe
Concentration (pg/ml) 5.00 8.50 199 1986
1:
– Mean (pg/ml) 5.42 7.52 176 1727
– Accuracy (%) 8.38 −11.6 −11.2 −13.0
– Precision (%) 2.40 1.90 1.50 10.8
2:
– Mean (pg/ml) 4.76 8.80 171 1708
– Accuracy (%) −4.88 3.47 −14.0 −14.0
– Precision (%) 3.80 2.70 0.70 0.50
3:
– Mean (pg/ml) 4.85 8.37 183 1757
– Accuracy (%) −3.01 −1.49 −7.82 −11.6
– Precision (%) 7.10 2.80 1.80 1.90
Batch-to-batch:
– Mean (pg/ml) 4.99 8.26 177 1731
– Accuracy (%) −0.20 −2.80 −10.8 −12.8
– Precision (%) 8.40 6.30 3.50 1.80
11-OH-yohimbine
Concentration (ng/ml) 5.0 9.74 195 1948
1:
– Mean (pg/ml) 5.87 10.3 204 2069
– Accuracy (%) 17.2 5.59 4.77 6.20
– Precision (%) 1.70 4.60 4.20 2.30
2:
– Mean (pg/ml) 5.75 10.1 199 1987
– Accuracy (%) 15.0 3.39 2.25 2.00
– Precision (%) 2.50 2.10 2.40 1.10
3:
– Mean (pg/ml) 5.09 9.65 203 1956
– Accuracy (%) 1.71 −0.98 3.99 0.41
– Precision (%) 2.70 2.90 4.40 3.30
Batch-to-batch:
– Mean (pg/ml) 5.54 9.99 202 2001
– Accuracy (%) 10.7 2.50 3.60 2.70
– Precision (%) 6.70 3.80 3.60 3.00
LLOQ: Lower limit of quantification; QC: Quality control.
Pharmacokinetics in two healthy subjects after administration of 50 μg oral yohimbine
Pharmacokinetics of oral yohimbine microdoses were determined in two healthy subjects (Figure 3) who had
been genotyped to show they had markedly different CYP2D6 enzyme activity to evaluate the suitability of the
assay for the investigation of the potential of yohimbine for profiling of CYP2D6 enzyme activity. The calibration
range from 5 to 2500 pg/ml was sufficient for the investigation of plasma concentrations after administration of
oral microdoses. Yohimbine half-life was substantially different in the two subjects, yet in accordance with the
determined enzyme activity by genotyping and the amount of metabolite generated. The pharmacokinetics of
yohimbine and its metabolite in both subjects are shown in Table 2.
Subject 1 possessing normal enzyme activity achieved maximum plasma concentrations of yohimbine and 11-
OH-yohimbine 15 min after administration while subject 2 (genotyped as a poor metaboliser) did after 45 min.
Further, maximum plasma concentration of yohimbine was more than threefold higher in subject 2 while subject 1
showed systematic exposure twice as much metabolite compared with subject 2 which is in line with the expected
1464 Bioanalysis (2019) 11(16) future science group
Quantification of oral microdosed yohimbine Preliminary Communication
600
400
200
0
0
P
la
sm
a 
co
n
ce
rt
ra
ti
o
n
 (
p
g
/m
l)
P
la
sm
a 
co
n
ce
n
tr
at
io
n
 (
p
g
/m
l)
6 12 18 24
Time (h)
Time (h)
1000
100
10
1
0 6 12 18 24
Yohimbine subject 1
11-OH-yohimbine subject 1
Yohimbine subject 2
11-OH-yohimbine subject 2
Figure 3. Plasma concentration–time curves of yohimbine and 11-OH-yohimbine after administration of 50 μg oral
yohimbine to two healthy participants, one with normal CYP2D6 enzyme activity (subject 1) and one with impaired
CYP2D6 enzyme activity (subject 2).
Table 2. Pharmacokinetic parameters of two healthy subjects with different CYP2D6 genotypes.
Analyte cmax (pg/ml) tmax (pg/ml) t1/2 (h) Cl/F (l) V/F (l)
Subject 1: Normal CYP2D6 activity
Yohimbine 87.3 0.25 0.67 13921 806
11-OH-yohimbine 551 0.25 15.1
Subject 2: Impaired CYP2D6 activity
Yohimbine 299 0.75 1.37 1801 214
11-OH-yohimbine 296 0.75 17.5
Cl/F: Apparent total clearance; cmax: Maximum concentration; t1/2: Terminal elimination half-life; tmax: Time to reach maximum concentration; V/F: Apparent volume of
distribution.
faster metabolization of yohimbine in subject 1. This higher enzyme activity is further visual in the shorter
pharmacokinetic elimination half-life of yohimbine in subject 1 (0.67 h) also indicating major metabolism of
yohimbine via CYP2D6.
Hence, the assay is suitable for the investigation of the variable plasma concentrations depending on the CYP2D6
enzyme activity after administration of oral microdoses of yohimbine, which enables evaluation of yohimbine for
profiling of CYP2D6 activity. This further allows the application in microdose substance cocktails [13] aiming at
the simultaneous determination of multiple CYP enzyme activities, for example, midazolam for CYP3A4 [14,15].
Conclusion
We developed and validated an ultrasensitive assay for the determination of yohimbine and its major metabolite
11-OH-yohimbine in human plasma using UPLC–MS/MS. Due to its high sensitivity, the assay allowed determi-
nation of 11-OH-yohimbine plasma concentrations from a healthy subject after oral administration of yohimbine
microdoses for 24 h. Previously described methods only deal with plasma concentrations after administration of
pharmacologically active doses (at least 5 mg), sample volumes of 0.5–2 ml and LLOQs of 0.05–0.2 ng/ml for
future science group www.future-science.com 1465
Preliminary Communication Vay, Sauter, Mikus & Burhenne
yohimbine [10] and 1.0 ng/ml for 11-OH-yohimbine [6]. The straight forward sample preparation combined with
small sample volume (100 μl) and short run time of the assay is suitable and effective for measurement of high
sample numbers in drug–drug interaction trials. It is, to our knowledge, by far the most sensitive assay for quan-
tification of yohimbine and its major metabolite 11-OH-yohimbine enabling determination of pharmacokinetics
after oral microdosing. Moreover, judging from the plasma concentration versus time curves, this assay provides a
basis for further investigation of possible CYP2D6 enzyme activity prediction using oral microdoses of yohimbine
as well as in microdose cocktails for simultaneous profiling of multiple CYP enzyme activities.
Future perspective
Microdosed yohimbine may be used in drug–drug interaction trials to evaluate CYP2D6 enzyme activity as well as
for phenotyping. The possibility to use yohimbine in microdose ‘cocktails’ for simultaneous characterization of mul-
tiple cytochrome P450 enzyme activities in drug–drug interaction trials can further simplify safe pharmacological
investigations.
Executive summary
Background
• Investigation of the pharmacokinetics of oral microdosed yohimbine for drug–drug interaction trials using
UPLC–MS/MS quantification in the picogram range.
Materials & methods
• Low amount (100 μl) of plasma was used and efficient extraction achieved by fast liquid–liquid extraction.
• Ultrasensitive quantification of yohimbine and its major metabolite (LLOQ: 5 pg/ml).
• Pharmacokinetics of yohimbine and its metabolite were evaluated in two subjects with different CYP2D6 enzyme
activity.
Results & discussion
• The UPLC–MS/MS assay was validated in accordance with US FDA’s and EMA’s pertinent guidelines showing good
accuracy and precision.
• The assay was successfully applied to determine yohimbine and 11-OH-yohimbine pharmacokinetics after oral
administration of 50 μg yohimbine in two healthy subjects.
Conclusion
• The developed assay allows sensitive determination of yohimbine and its metabolite 11-OH-yohimbine in the
picogram range after oral microdoses.
• Yohimbine microdosing combined with ultrasensitive quantification is potentially suitable for profiling of
CYP2D6 enzyme activity.
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